Product Images Cetirizine Hydrochloride

This is a description of Cetirizine Hydrochloride Syrup, a medication that is intended for oral use only. It is grape flavored and each milliliter of the syrup contains 1 mg of cetirizine hydrochloride. The usual dosage information can be found in the accompanying prescribing information. The syrup should be stored at a temperature of 20-25°C (68-77°F), with allowed excursions of 15-30°C (59-86°F) according to USP Controlled Room Temperature guidelines. Alternatively, it can be stored refrigerated at 2-8°C (36-46°F). The medication should be dispensed in a tight, light-resistant container as defined in the USP. The bottle contains 16 fluid ounces (473 mL) of the syrup, and it is only available with a prescription. Full prescribing information can be found by lifting a specific section of the packaging.*

Not available.*

Cetirizine Hydrochloride Syrup is a medication used to treat allergies and urticaria. The maximum recommended daily oral dose for rats was found to be 562 mg, which is significantly higher than the recommended doses for adults and infants. In rodents, the main target of acute toxicity was the central nervous system, while the main target of multiple-dose toxicity was the liver. The dosage and administration guidelines recommend taking the syrup without regard to food consumption. The initial recommended dose for children aged 2-5 years is 2.5 mg (1 teaspoon), with the possibility of increasing it to a maximum of 5 mg per day. For children aged 6 months to <2 years, the initial recommended dose is 2.5 mg (4 teaspoonfuls) once daily, which can be increased to a maximum of 5 mg per day. The syrup is supplied in 4-ounce and 16-ounce amber plastic bottles. It should be stored at a controlled room temperature of 21%-25°C (58°F-77°F). Manufactured by Bajaj Medical, LLC in Chicago, Illinois, USA.*

This text appears to be a description of a medication called Cetirizine Hydrochloride Syrup. It is a grape-flavored syrup that is intended for oral use. Each milliliter (mL) of the syrup contains 1 milligram (mg) of cetirizine hydrochloride. The usual dosage information is provided, but it is not readable in this text. The syrup should be stored at a temperature of 20-25°C (68-77°F), with permitted excursions to 15-30°C (59-86°F) or refrigerated at 2-8°C (36-46°F). It should be dispensed in a tight, light-resistant container. The bottle contains 16 fluid ounces (473 mL). The manufacturer is Bajaj Medical, LLC based in Chicago, IL, USA. The issue date of the information is 09/2023.*

This is a description for Cetirizine Hydrochloride Syrup, a medication used for oral consumption. It contains 1 mg of cetirizine hydrochloride per milliliter and has a grape flavor. The usual dosage should be determined based on the accompanying prescribing information. It is recommended to store the syrup at a temperature between 20-25°C (68-77°F), with excursions permitted to 15-30°C (59-86°F). Alternatively, it can be refrigerated between 2-8°C (36-46°F). The medication should be dispensed in a tight and light-resistant container. The packaging contains 4 fluid ounces (120 mL) and is intended for prescription use only. The full prescribing information can be found by lifting a designated area on the packaging. The medication is manufactured by Bajaj Medical, LLC in Chicago, Illinois, USA. The expiration date of the product is September 2023.*

DESCRIPTION: Cetirizine hydrochloride is an orally active and selective H-receptor antagonist. It is a racemic compound with a molecular formula of C21H25N3O2•2HCI and a molecular weight of 461.82. Cetirizine hydrochloride is a white, crystalline powder that is water soluble. It is available in syrup form for oral administration, with a concentration of 1 mg/mL (3 mg/5 mL). The syrup contains inactive ingredients such as artificial grape flavor, acetic acid, glycerin, methylparaben, purified water, propylene glycol, propylparaben, sodium acetate, and sucrose. CLINICAL PHARMACOLOGY: Cetirizine acts as an antihistamine by selectively inhibiting peripheral H1 receptors. It has been shown to have negligible anticholinergic and antiserotonergic activity. Autoradiographic studies have shown that cetirizine does not significantly penetrate the brain. In clinical studies, dry mouth was more common with cetirizine compared to placebo. Cetirizine binds specifically to H1 receptors and has no measurable affinity for other receptors. PHARMACOKINETICS: Cetirizine is rapidly absorbed with a time to maximum concentration (Tmax) of approximately 1 hour following oral administration. There is comparable bioavailability between tablet and syrup forms. Multiple doses of cetirizine resulted in a mean peak plasma concentration of 311 ng/mL. Cetirizine has linear pharmacokinetics for oral doses ranging from 5 to 60 mg. Food does not affect the extent of cetirizine exposure but delays Tmax by 1.7 hours and decreases Cmax by 23%. Cetirizine is minimally protein bound, with approximately 3% bound to plasma proteins. It is metabolized to a limited extent, with approximately 50% of radioactivity excreted unchanged in the urine. The metabolite has negligible antihistaminic activity. The specific enzyme responsible for metabolism has not been identified.*

Cetirizine hydrochloride is a medication used to treat symptoms associated with allergies, such as sneezing, runny nose, and itchy eyes. It is also effective in treating chronic hives. The medication has been studied in both adults and children, showing significant improvements in symptoms. However, caution should be exercised when taking cetirizine hydrochloride, as it may cause drowsiness. Driving or operating machinery while taking the medication should be done with care. It is contraindicated in patients with a known hypersensitivity to the medication or its ingredients.*

Not available.*

Table 1 shows adverse experiences reported in pediatric patients aged 6 to 11 years who participated in placebo-controlled trials of Cetirizine Hydrochloride in the United States. The table displays the frequency of adverse experiences that occurred at a rate of more than 2% in either the 5 mg or 10 mg Cetirizine Hydrochloride group and more frequently than in the placebo group. The table includes adverse experiences such as headache, pharyngitis, abdominal pain, coughing, somnolence, diarrhea, and more. The text also mentions that rare adverse events were observed in both adults and pediatric patients who received Cetirizine Hydrochloride, but a causal relationship has not been established. The text further lists various adverse experiences related to different body systems, including the autonomic nervous system, cardiovascular system, central and peripheral nervous systems, gastrointestinal system, genitourinary system, hearing and vestibular system, metabolic/nutritional system, musculoskeletal system, psychiatric system, respiratory system, reproductive system, reticuloendothelial system, skin, and special senses.*

This is a description of a medication called Cetirizine Hydrochloride Syrup. It is a grape-flavored syrup designed for oral use only. Each milliliter of the syrup contains 1 mg of cetirizine hydrochloride. The usual dosage information can be found in the accompanying prescribing information. The syrup should be stored at a temperature of 20-25°C (68-77°F), with excursions permitted to 15-30°C (59-86°F). It can also be refrigerated at a temperature of 2-8°C (36-46°F). The syrup should be dispensed in a tight, light-resistant container as defined in the USP. The bottle contains 120 mL of the medication and it is manufactured by Bajaj Medical, LLC located in Chicago, IL 60609, USA. The expiry date of the medication is 09/2023.*